JP2010526101A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526101A5
JP2010526101A5 JP2010506688A JP2010506688A JP2010526101A5 JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5 JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5
Authority
JP
Japan
Prior art keywords
use according
compound
composition
unit dose
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010506688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526101A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/062518 external-priority patent/WO2008137753A2/en
Publication of JP2010526101A publication Critical patent/JP2010526101A/ja
Publication of JP2010526101A5 publication Critical patent/JP2010526101A5/ja
Withdrawn legal-status Critical Current

Links

JP2010506688A 2007-05-02 2008-05-02 直接作用型および可逆的p2y12阻害剤の静脈および経口投与 Withdrawn JP2010526101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (2)

Publication Number Publication Date
JP2010526101A JP2010526101A (ja) 2010-07-29
JP2010526101A5 true JP2010526101A5 (cg-RX-API-DMAC7.html) 2011-06-23

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506688A Withdrawn JP2010526101A (ja) 2007-05-02 2008-05-02 直接作用型および可逆的p2y12阻害剤の静脈および経口投与

Country Status (17)

Country Link
US (2) US20090048216A1 (cg-RX-API-DMAC7.html)
EP (1) EP2079464A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010526101A (cg-RX-API-DMAC7.html)
KR (1) KR20100029746A (cg-RX-API-DMAC7.html)
CN (1) CN101795682A (cg-RX-API-DMAC7.html)
AU (1) AU2008247483A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0811476A2 (cg-RX-API-DMAC7.html)
CA (1) CA2686203A1 (cg-RX-API-DMAC7.html)
CO (1) CO6241104A2 (cg-RX-API-DMAC7.html)
EA (1) EA200901473A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099778A (cg-RX-API-DMAC7.html)
GT (1) GT200900284A (cg-RX-API-DMAC7.html)
IL (1) IL201834A0 (cg-RX-API-DMAC7.html)
MA (1) MA31663B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009011843A (cg-RX-API-DMAC7.html)
TN (1) TN2009000451A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008137753A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017402B1 (ru) * 2005-11-03 2012-12-28 Портола Фармасьютикалз, Инк. [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение
BRPI0808422A2 (pt) * 2007-03-06 2015-06-23 Novartis Ag Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas
CN101720324A (zh) * 2007-05-02 2010-06-02 波托拉医药品公司 [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN106075455A (zh) * 2008-12-30 2016-11-09 丹麦国家医院 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
DK2498731T3 (da) 2009-11-11 2020-03-02 Chiesi Farm Spa Fremgangsmåder til behandling eller forebyggelse af stenttrombose
CA2785487C (en) * 2009-12-23 2017-11-28 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072743A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
US8987285B2 (en) * 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
EA017402B1 (ru) 2005-11-03 2012-12-28 Портола Фармасьютикалз, Инк. [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение

Similar Documents

Publication Publication Date Title
JP2010526101A5 (cg-RX-API-DMAC7.html)
US12220392B2 (en) Combination composition
JP2020033360A5 (cg-RX-API-DMAC7.html)
JP2008535867A5 (cg-RX-API-DMAC7.html)
JP2011173928A5 (cg-RX-API-DMAC7.html)
JP2009102342A5 (cg-RX-API-DMAC7.html)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2014515373A5 (cg-RX-API-DMAC7.html)
ES2671926T3 (es) Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico
ES2508490T3 (es) Formulación de trimetazidina con diferentes perfiles de liberación
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP2020510043A5 (cg-RX-API-DMAC7.html)
CA2964684A1 (en) Composition for the treatment of conditions involving muscular pain
AU2010277725B2 (en) Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients
WO2012005605A1 (en) A combination composition comprising ibuprofen and paracetamol
CN102247330B (zh) 一种以红花黄色素为原料制备的缓释片剂及其制备方法
TWI631944B (zh) 氯硝柳胺及其衍生物的用途
KR20120089444A (ko) 정맥내 이부프로펜에 의한 위독한 환자의 치료방법
ES2782898T3 (es) Métodos de administración de compuestos agonistas de la trombopoyetina
ES2952013T3 (es) Combinación de ibuprofeno y tramadol para aliviar el dolor
JP2008527034A5 (cg-RX-API-DMAC7.html)
CN103933034B (zh) 一种含有木犀草素的药物组合物及应用
Sparagana Superior vena cava syndrome caused by mediastinal goiter
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
RU2004108117A (ru) Нептидиларгинали и способы лечения синдрома диссеминированного внутрисосудистого свертывания